AI-CVD: AI-Powered Cardiovascular Risk Assessment from CAC and Chest CT
- Jul 15
- 1 min read
Updated: Jul 17
Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group
AI-CVD is an advanced artificial intelligence platform that transforms routine coronary artery calcium (CAC) and chest CT scans into comprehensive cardiovascular risk assessments by extracting a wide range of imaging biomarkers from a single examination.
Rather than relying solely on traditional clinical risk factors, AI-CVD analyzes multiple cardiometabolic and systemic biomarkers—including coronary and extracoronary calcifications, cardiac chamber volumes, great vessel measurements, epicardial and visceral fat, liver fat, muscle quality, bone mineral density, and lung abnormalities—to provide a more personalized evaluation of cardiovascular health.
The presentation highlights a growing body of scientific evidence demonstrating that these AI-derived imaging biomarkers can improve prediction of major cardiovascular outcomes, including atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and atrial fibrillation (AF). Validated across large population studies such as the Multi-Ethnic Study of Atherosclerosis (MESA) and the Framingham Heart Study (FHS), AI-CVD models consistently match or outperform conventional clinical risk scores, supporting a new imaging-driven approach to preventive cardiology.
By converting routine CT scans into actionable clinical insights, AI-CVD enables earlier identification of high-risk individuals, more personalized preventive strategies, and improved allocation of healthcare resources. This presentation showcases the scientific foundation, clinical validation, and future potential of AI-CVD as a next-generation platform for precision cardiovascular prevention.
Download the complete presentation below to explore the AI-CVD platform, imaging biomarkers, validation studies, and outcome-specific risk prediction models.
Comments